References
- 1. SEER Cancer Statistics Review, 1975-2014. National Cancer Institute, Bethesda, MD 2017, Section 28.
- 2. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010; 115(16): 3206–14.10.1182/blood-2009-10-248146
- 3. Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013; 14(3): 199–209.10.1016/S1470-2045(12)70600-9
- 4. Pieters R, de Groot-Kruseman H, Van der Velden V, et al. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. Journal of Clinical Oncology 2016; 34(22): 2591–601.10.1200/JCO.2015.64.6364
- 5. Domenech C, Suciu S, De Moerloose B, et al. Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica. 2014 Jul; 99(7): 1220–7.10.3324/haematol.2014.103507
- 6. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children’s Oncology Group. J Clin Oncol 2012; 30, 1663–1669.10.1200/JCO.2011.37.8018
- 7. Pui CH, Pei D, Coustan-Smith E, Jeha S, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol. 2015 Apr; 16(4): 465–74.10.1016/S1470-2045(15)70082-3
- 8. Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05–001): a randomised, open-label phase 3 trial. Lancet Oncol 2015; 16(16): 1677–90.10.1016/S1470-2045(15)00363-0
- 9. Stary J, Zimmermann M, Campbell M, et al. Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intercontinental Trial ALL IC-BFM 2002. J Clin Oncol. 2014; 32(3): 174–184.10.1200/JCO.2013.48.652224344215
- 10. Pui C-H, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 354: 166–178, 2006.10.1056/NEJMra05260316407512
- 11. Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008; 111: 4477–4489.10.1182/blood-2007-09-11292018285545
- 12. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children’s Research Hospital. Blood. 2004; 104: 2690–2696.10.1182/blood-2004-04-1616
- 13. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996 Jan; 14(1): 18–24.10.1200/JCO.1996.14.1.18
- 14. Maloney KW, Shuster JJ, Murphy S, et al. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986–1994. Leukemia 2000; 14: 2276.10.1038/sj.leu.2401965
- 15. Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010; 11: 429.10.1016/S1470-2045(10)70066-8
- 16. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer. 1997; 80(9): 1717–26.10.1002/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO;2-B
- 17. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia. 2000 Dec; 14(12): 2205–22.10.1038/sj.leu.2401973
- 18. van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998 Nov 28; 352(9142): 1731–8.10.1016/S0140-6736(98)04058-6
- 19. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000; 96: 2691–2696.10.1182/blood.V96.8.2691
- 20. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008; 111(12): 5477–5485.10.1182/blood-2008-01-132837
- 21. Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011; 118(8): 2077–84.10.1182/blood-2011-03-338707
- 22. Vora A, Goulden N, Mitchell C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014; 15(8): 809–18.10.1016/S1470-2045(14)70243-8
- 23. Republic of Macedonia. State Statistical Office. Census of population, households and dwellings in the Republic of Macedonia, 2002 - BooK XIII. Skopje, Republic of Macedonia: State Statistical Office; 2005.
- 24. Jovanovska A, Martinova K, Kocheva S, et al. Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia. Open Access Maced J Med Sci. 2019 Sep 14; 7(17): 2818–2823.10.3889/oamjms.2019.752
- 25. Silverman L.B., Gelber R.D., Dalton V.K., et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001; 97(5): 1211–1218.10.1182/blood.V97.5.1211
- 26. Lim JY, Bhatia S, Robison LL, et al. Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia. Cancer. 2014 Apr 1; 120(7): 955–62.10.1002/cncr.28531
- 27. Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol. 2019 Mar; 20(3): e142-e154.10.1016/S1470-2045(19)30031-2
- 28. Hargrave DR, Hann II, Richards SM, et al. Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI). Br J Haematol 2001; 112: 293–299.10.1046/j.1365-2141.2001.02543.x11167821
- 29. Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children’s Oncology Group Report. Leukemia. 2010 Feb; 24(2): 285–97.10.1038/leu.2009.262290613920016531
- 30. Antillón FG, Blanco JG, Valverde PD, et al. The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results. Cancer. 2017 Feb 1; 123(3): 436–448.10.1002/cncr.3025727683100
- 31. Aricò M, Valsecchi MG, Rizzari C, et al. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. J Clin Oncol. 2008 Jan 10; 26(2): 283–9.10.1200/JCO.2007.12.392718182669
- 32. Möricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010 Feb; 24(2):265–84.10.1038/leu.2009.25720010625
- 33. Lauten M, Möricke A, Beier R, et al. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica. 2012 Jul; 97(7): 1048–56.10.3324/haematol.2011.047613339667722271901
- 34. Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: a Children’s Oncology Group Report. Leukemia. 2010 Feb; 24(2): 285–97.10.1038/leu.2009.262290613920016531